General Information of the Compound
| Compound ID |
CP0479103
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[4-[4-(cyclopropylmethyl)piperazin-1-yl]phenyl]-11,15-dimethoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-triene
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C38H49N3O3
|
||||||||||||||||||
| Molecular Weight |
595.828
|
||||||||||||||||||
| Canonical SMILES |
COc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)[C@]1(CC[C@@]35C[C@@H]1c1ccc(cc1)N1CCN(CC2CC2)CC1)OC
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C38H49N3O3/c1-42-31-12-9-28-21-32-36-13-14-38(43-2,35-37(36,33(28)34(31)44-35)15-16-41(32)24-26-5-6-26)30(22-36)27-7-10-29(11-8-27)40-19-17-39(18-20-40)23-25-3-4-25/h7-12,25-26,30,32,35H,3-6,13-24H2,1-2H3/t30-,32-,35-,36-,37+,38-/m1/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
OYZWQPOQFLJIFK-OWDVXBOWSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01526, Delta-type opioid receptor
Protein ID: PT00983, Kappa-type opioid receptor
Protein ID: PT01549, Mu-type opioid receptor